Modulus Discovery, founded in 2016, is a Tokyo-based biotechnology and pharmaceutical startup operating in the preclinical stage. The company stands out for its expertise in the swift design and creation of small molecule clinical candidates. Leveraging cutting-edge computational drug discovery and unique biological insights, Modulus Discovery aims to target a variety of significant diseases.
The company boasts an international team comprised of experts with deep R&D backgrounds from global pharmaceutical, biotechnology, and computational technology sectors. This diverse skill set positions Modulus Discovery as a promising innovator in the fields of biotechnology and care economy.
Their progress has attracted investment, with a notable ¥2.34B Series C investment from a consortium of investors including Green Co-Invest Investment, Keio Innovation Initiative, UTokyo Innovation Platform, Fast Track Initiative, Inc., Heights Capital Management, and SBI Group. This financial backing underscores market confidence in their computational approach and strategic vision for medical advancements.
